Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience

BackgroundRelapsed/refractory high-risk neuroblastoma has a dismal prognosis. Anti-GD2-mediated chemo-immunotherapy has a notable anti-tumor activity in patients with relapsed/refractory high-risk neuroblastoma. The purpose of this study was to analyze the efficacy and safety of the combination of i...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Nur Olgun, Emre Cecen, Dilek Ince, Deniz Kizmazoglu, Birsen Baysal, Ayse Onal, Ozhan Ozdogan, Handan Guleryuz, Riza Cetingoz, Ayse Demiral, Mustafa Olguner, Ahmet Celik, Serra Kamer, Erdener Ozer, Zekiye Altun, Safiye Aktas
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2022-12-01
Schriftenreihe:	Frontiers in Oncology
Schlagworte:	neuroblastoma relapsed refractory dinutuximab beta anti-GD2
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1041443/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!